Neurolens designs prescription lenses that add a contoured prism to bring the eyes into alignment.
Neurolens has raised $45.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2023.
Neurolens's investors include MVM Life Science Partners, Marshall Wace, Bluestem Capital, Falcon Vision, Trinary Capital.
Neurolens is headquartered in Coppell, United States.
Neurolens designs prescription lenses that add a contoured prism to bring the eyes into alignment.
Neurolens is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurolens — Funding & Investors." VCBacked, December 5, 2023, https://www.vcbacked.co/company/neurolens. Accessed September 29, 2026.
VCBacked. (2023). Neurolens — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/neurolens
{{cite web |title=Neurolens — Funding & Investors |url=https://www.vcbacked.co/company/neurolens |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated